Project Grant R01CA316462
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $499K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $682,969 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026, through June 30, 2031. This award supports fundamental research into the hormonal regulation of myeloid immune checkpoint mechanisms within the tumor microenvironment (TME). The project investigates how Secretogranin II (SCG2), a hormone overexpressed in breast...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center, effective May 1, 2026 through April 30, 2031, under the Cancer Biology Research program (CFDA 93.396). This research grant funds a five-year investigative study entitled "Control of T-Cell Stemness and T-Cell Exhaustion by KEAP1-NRF2 Axis," which will be conducted at the institution's Dallas, Texas campus. The research...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Texas at Austin a $2.59 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. The award supports research to develop a novel cancer immunotherapy approach targeting immune-excluded or "cold" tumors that typically demonstrate poor response to immune checkpoint therapy. The project focuses on demonstrating that degradation of...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $639,514 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas Southwestern Medical Center, effective June 1, 2026, through May 31, 2031. This five-year research initiative focuses on characterizing the mechanistic basis of NVL (Nuclear VCP-Like) inhibition by benzothiazepinone compounds—specifically MM17—as a novel non-genotoxic chemotherapy strategy. The research delivers...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $501,803 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026, through May 31, 2031. This research project focuses on decoding the stromal microenvironment of pancreatic ductal adenocarcinoma (PDAC) by elucidating the role of antigen-presenting cancer-associated fibroblasts (APCAFs) in tumor progression and...
- Summary of Federal Project Grant Award The University of Texas Southwestern Medical Center received a $687,594 project grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. This award supports fundamental research on brain metastasis organotropism and therapy response in small cell lung cancer (SCLC), addressing the critical clinical need for more effective and less toxic treatment alternatives to...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas Southwestern Medical Center a $688,012 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, with a completion date of May 31, 2031. This award supports the development of novel RPS23 (ribosomal protein S23) inhibitors for the treatment of acute myeloid leukemia (AML). The research leverages an integrated platform combining high-throughput phenotypic screening with rapid...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $376,886 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period July 1, 2026 through June 30, 2029. The award supports the development of novel small-molecule inhibitors targeting Site-One Protease (S1P) to prevent and treat cancers, particularly clear cell renal cell carcinoma and hepatocellular carcinoma. The research builds...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $616,715 to The University of Texas MD Anderson Cancer Center, with an award date of August 11, 2025 and completion date of July 31, 2030. This award supports research under the Cancer Treatment Research program (CFDA 93.395), which develops and evaluates improved methods of cancer treatment through fundamental and applied laboratory and clinical research. The funded research centers on the...